• Mineralys highlighted FDA acceptance of its NDA for lorundrostat, with a PDUFA target date of Dec. 22, 2026.
• Lorundrostat positioned as a once-daily selective aldosterone synthase inhibitor for uncontrolled or resistant hypertension, targeting dysregulated aldosterone.
• Pivotal data showed placebo-adjusted systolic blood pressure reductions of 11.6 mmHg at week 6 and 7.9 mmHg at week 12.
• Proof-of-concept studies showed benefit in hypertension patients with chronic kidney disease, including a 31% UACR reduction at 4 weeks.
• Cash balance was USD 661 million at June 30, 2026; common shares outstanding totaled 88,956,640 as of Aug. 3, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.